Not Yet RecruitingNot Applicable

Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout

United States310 participantsStarted 2026-10-01

Plain-language summary

This study will compare two different approaches to manage medications that lower uric acid levels. This study will be conducted at five VA medical centers across the United States and will take 4-5 years to complete. Individual participation will last up to two years.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * US Veterans over the age of 18 years with physician-diagnosed * Documented hyperuricemia (SU \>6.8 mg/dL) * Satisfy ACR/EULAR gout classification criteria * Report 1 or more flares in the prior 6 months * Receipt of a new ULT prescription (allopurinol or febuxostat) initiated by a primary care provider or longer term ULT but otherwise satisfy the flare/SU criteria Exclusion Criteria: * Any patient intolerant or unable to take ULTs (allopurinol or febuxostat) * Patients with a rheumatology encounter within the prior 3 months

What they're measuring

flare occurrence

Timeframe: during year two

serum urate at goal

Timeframe: at end of year one

Trial details

NCT IDNCT06887452

SponsorVA Office of Research and Development

Sponsor typeFED

Study typeINTERVENTIONAL

Primary completion2029-10-01

Contact for this trial

Bridget Kramer

(402) 995-3206 bridget.kramer@va.gov

View on ClinicalTrials.gov More Gout trials